Guillermo Crespo
Hospital Universitario de Canarias
28 Papers
97 Citations
Guillermo Crespo is an academic researcher from Hospital Universitario de Canarias. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 24 publications.
Chat about Author
Papers
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Alberto Carmona-Bayonas,Paula Jiménez-Fonseca,Angela Lamarca,Jorge Barriuso,A Castaño,Marta Benavent,Vicente Alonso,Maria C Riesco-Martinez,Teresa Alonso-Gordoa,Ana Custodio,Manuel Sánchez Cánovas,Jorge Hernando Cubero,Carlos F. Lopez,Adelaida Lacasta,Ana Montes,Mónica Marazuela,Guillermo Crespo,Pilar Escudero,José A. Díaz,Eduardo Feliciangeli,Javier Gallego,Marta Llanos,Ángel Segura,Felip Vilardell,Juan Carlos Percovich,Enrique Grande,Jaume Capdevila,Juan W. Valle,Rocio Garcia-Carbonero +28 more
TL;DR: The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS, and could be a valuable tool for making treatment decisions in daily clinical practice.
Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors
José A. Galván,Aurora Astudillo,Aitana Vallina,Guillermo Crespo,Maria Victoria Folgueras,María Victoria González +5 more
TL;DR: The immunohistochemical determination of E-cadherin/β-catenin complex integrity loss and EMT markers in the clinical setting might be a potential useful diagnostic and prognostic tool especially among the TC patients.
Prognostic factors in patients with advanced renal cell carcinoma.
Carolina Muriel Lopez,Emilio Esteban,J.P. Berros,P. Pardo,Aurora Astudillo,Marta Izquierdo,Guillermo Crespo,Miguel F. Sanmamed,Paula Jiménez Fonseca,Pablo Martínez-Camblor +9 more
TL;DR: HIF-1α, PTEN, p21, thrombocytosis, neutrophilia, and CAIX in particular are useful prognostic factors in patients with advanced RCC.
36
A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).
Rocio Garcia-Carbonero,M. Benavent,Paula Jiménez Fonseca,Daniel Castellano,Teresa Alonso,Alex Teulé,Ana Custodio,Salvatore Tafuto,Adelaida La Casta Munoa,Francesca Spada,Carlos López-López,Toni Ibrahim,Maria Jose Villanueva Silva,Vega Iranzo,Pilar García-Alfonso,Encarnación González,Enrique Grande,Guillermo Crespo,Jaume Capdevila +18 more
TL;DR: Axitinib is a potent and selective VEGFR-1,2,3 inhibitor, with proven activity against several vascular-depen...
32
Predictive factors for response to treatment in patients with advanced renal cell carcinoma
Carolina Muriel Lopez,Emilio Esteban,Aurora Astudillo,P. Pardo,J.P. Berros,Marta Izquierdo,Guillermo Crespo,Paula Jiménez Fonseca,Miguel F. Sanmamed,Pablo Martínez-Camblor +9 more
TL;DR: The findings highlight the usefulness of CAIX in selecting patients with advanced RCC as candidates for systemic treatment and suggest PTEN and p21 may be important in predicting response to sunitinib.
26